[toc]

- [Summaries](#summaries)
  - [Table 1. Virus Variants and Spike Mutations vs Monoclonal Antibodies](#table.1.virus.variants.and.spike.mutations.vs.monoclonal.antibodies)
  - [Table 2. Variants of Concern, Variants of Interest, and Other Variants for which Neutralization Data are Available](#table.2.variants.of.concern.variants.of.interest.and.other.variants.for.which.neutralization.data.are.available)
  - [Table 3. Individual SARS-CoV-2 Spike Mutations for which Data are Available](#table.3.individual.sars-cov-2.spike.mutations.for.which.data.are.available)
  - [Table 4. Monoclonal Antibodies (mAbs) with Emergency Use Authorization (EUA) or in Advanced Clinical Trials](#table.4.monoclonal.antibodies.mabs.with.emergency.use.authorization.eua.or.in.advanced.clinical.trials)
  - [Table 5. Numbers of Vaccinee Plasma (VP) Neutralization Experiments According to the Vaccine, History of Previous Infection, Time Since Infection, and SARS-CoV-2 Variant Tested](#table.5.numbers.of.vaccinee.plasma.vp.neutralization.experiments.according.to.the.vaccine.history.of.previous.infection.time.since.infection.and.sars-cov-2.variant.tested)
  - [Table 6. Numbers of Convalescent Plasma (CP) Neutralization Experiments According to the Infecting Virus, Time Since Infection, and SARS-CoV-2 Variant Tested](#table.6.numbers.of.convalescent.plasma.cp.neutralization.experiments.according.to.the.infecting.virus.time.since.infection.and.sars-cov-2.variant.tested)
  <!-- - [Document 1] -->
  - [Figure 1: Distribution of fold-reduction in susceptibilities (A) and of absolute neutralizing titers (B) of vaccinee plasma (VP) associated with eight vaccines to the five variants of concern (VOC)](#figure.1.distribution.of.fold-reduction.in.susceptibilities.a.and.of.absolute.neutralizing.titers.b.of.vaccinee.plasma.vp.associated.with.eight.vaccines.to.the.five.variants.of.concern.voc.)
  - [Figure 2: Monoclonal antibodies (mAbs) with EUAs or in advanced clinical development: receptor binding domain (RBD) epitopes and immune escape positions.](#figure.2.monoclonal.antibodies.mabs.with.euas.or.in.advanced.clinical.development.receptor.binding.domain.rbd.epitopes.and.immune.escape.positions.)

  - [Table 7. Virus Variants and Spike Mutations vs Convalescent Plasma](#table.7.virus.variants.and.spike.mutations.vs.convalescent.plasma)
  - [Table 8. Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons](#table.8.virus.variants.and.spike.mutations.vs.plasma.from.vaccinated.persons)
  - [Table 9. Omicron Spike Mutations vs Monoclonal Antibodies](#table.9.omicron.spike.mutations.vs.monoclonal.antibodies)
  - [Table 10. Omicron Spike Mutations DMS Score](#table.10.omicron.spike.mutations.dms.score)

- Lookup tables
  - [mAb (monoclonal antibody) synonyms](/page/mab-synonyms)
  - [Wildtype mutations](/page/wildtype)
- [References](#references)

[/toc]

## Summaries

### Table 1. Virus Variants and Spike Mutations vs Monoclonal Antibodies




### Table 2. Variants of Concern, Variants of Interest, and Other Variants for which Neutralization Data are Available




### Table 3. Individual SARS-CoV-2 Spike Mutations for which Data are Available




### Table 4. Monoclonal Antibodies (mAbs) with Emergency Use Authorization (EUA) or in Advanced Clinical Trials



### Table 5. Numbers of Vaccinee Plasma (VP) Neutralization Experiments According to the Vaccine, History of Previous Infection, Time Since Infection, and SARS-CoV-2 Variant Tested



### Table 6. Numbers of Convalescent Plasma (CP) Neutralization Experiments According to the Infecting Virus, Time Since Infection, and SARS-CoV-2 Variant Tested



### Figure 1: Distribution of fold-reduction in susceptibilities (A) and of absolute neutralizing titers (B) of vaccinee plasma (VP) associated with eight vaccines to the five variants of concern (VOC)


### Figure 2: Monoclonal antibodies (mAbs) with EUAs or in advanced clinical development: receptor binding domain (RBD) epitopes and immune escape positions.




### Table 7. Virus Variants and Spike Mutations vs Convalescent Plasma


***


### Table 8. Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons



***



### Table 9. Omicron Spike Mutations vs Monoclonal Antibodies



***


### Table 10. Omicron Spike Mutations DMS Score


***


<section>

<div class="figure-caption">

## References


</div>

</section>
